CAJ | 학술논문

目的研究恩替卡韦和阿德福韦酯对慢性乙型肝炎（CHB）患者肾功能的影响。方法选取在我院进行治疗的慢性乙型肝炎患者98例，随机分为恩替卡韦（ET V ）组49例和阿德福韦酯（ADV ）组49例。2组患者分别采用适量对应药物进行抗病毒治疗。收集2组患者治疗前和治疗后12周、48周的乙肝病毒（HBV）DNA含量、血清肌酐（CR）和肾小球滤过率（eGFR）的水平，以及2组患者治疗12周、48周后 HBV‐DNA的转阴率、丙氨酸氨基转移酶（ALT）复常率和完全应答率的数据。结果所有患者HBV‐DNA水平在治疗后有所降低，2组患者的HBV‐DNA含量和转阴率、ALT复常率和完全应答率数据比较，差异明显，具有统计学意义。CR和eGFR含量仅在治疗48周后比较数据，差异明显，具有统计学意义。在治疗前和治疗后12周比较数据，差异无统计学意义。结论恩替卡韦比阿德福韦酯具有更强的抑制HBV‐DNA作用，能够更好的改善肾功能。
목적연구은체잡위화아덕복위지대만성을형간염（CHB）환자신공능적영향。방법선취재아원진행치료적만성을형간염환자98례，수궤분위은체잡위（ET V ）조49례화아덕복위지（ADV ）조49례。2조환자분별채용괄량대응약물진행항병독치료。수집2조환자치료전화치료후12주、48주적을간병독（HBV）DNA함량、혈청기항（CR）화신소구려과솔（eGFR）적수평，이급2조환자치료12주、48주후 HBV‐DNA적전음솔、병안산안기전이매（ALT）복상솔화완전응답솔적수거。결과소유환자HBV‐DNA수평재치료후유소강저，2조환자적HBV‐DNA함량화전음솔、ALT복상솔화완전응답솔수거비교，차이명현，구유통계학의의。CR화eGFR함량부재치료48주후비교수거，차이명현，구유통계학의의。재치료전화치료후12주비교수거，차이무통계학의의。결론은체잡위비아덕복위지구유경강적억제HBV‐DNA작용，능구경호적개선신공능。
Objective To study the therapeutic effect of entecavir and adefovir dipivoxil on renal function .Methods 98 cases of chronic hepatitis B patients in our hospital were selected ,and randomly divided into entecavir (ETV) group of 49 cases and adefo‐vir dipivoxil (ADV) group of 49 cases .The two groups of patients received the corresponding antiviral drug therapy .Before the treatment and after the treatment 12 and 48 weeks ,hepatitis B virus (HBV) DNA ,serum creatinine (CR) ,glomerular filtration rate (eGFR) levels ,as well as the negative rate of HBV‐DNA ,and calamine aminotransferase (ALT ) were statistically analyzed . Results For all patients ,HBV‐DNA levels decreased after the treatment ,HBV‐DNA content ,ALT normalization rate and the complete response rate data of the two groups showed significant difference ,after the treatment of 12 weeks the difference was not statistically significant .Conclusion Compared with adefovir ,entecavir has a stronger role in inhibiting HBV‐DNA ,and improve‐ment in renal function .